-0.00362824448785921 0.000279095729835476 0.0131174993022608 0.0240022327658389 0.0125593078425901 0.0295841473625454 0.0200948925481442 0.0309628802679319
Sign Up Today X
Thanks for submitting the form.
Stockreport

NovoCure: There Is Still More Upside [Seeking Alpha]

NovoCure Limited - Ordinary Shares (NVCR)  More Company Research Source: Seeking Alpha
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment which resulted in positive price action. The lung cancer market will significanly increase Novocure's scale, on top of a strong core business that has beat growth expectations. With downside risks limited to execution or FDA recall, and a price target of $35.10, I raise my rating from buy to strong buy. wildpixel I am updating my analysis on NovoCure Limited (NASDAQ: NVCR ) in light of FDA approval of its lung cancer treatment and the resulting price action. I previously rated NovoCure a buy for the following reasons: Quarterly results exceeded my expectations with higher revenue growth and aggressive cost management Market tailwinds in the speciality oncology space were accelerating Approved treatments in the core business were continuing to succeed DCF generated price target of $22.10 was 46% upside from today's pricing. Since then, Novocure has risen 34% versus the S&P 500 at 1 [Read more]
IMPACT SNAPSHOT EVENT TIME: NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
NVCR alerts
from News Quantified
NVCR
NEWS
NVCR
Earnings
NVCR
Analyst Actions
NVCR
SEC Filings
Stockreport

NovoCure: There Is Still More Upside [Seeking Alpha]

NovoCure Limited - Ordinary Shares  (NVCR) 
More Company Research Source: Seeking Alpha
Last novocure limited - ordinary shares earnings: 4/30 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment which resulted in positive price action. The lung cancer market will significanly increase Novocure's scale, on top of a strong core business that has beat growth expectations. With downside risks limited to execution or FDA recall, and a price target of $35.10, I raise my rating from buy to strong buy. wildpixel I am updating my analysis on NovoCure Limited (NASDAQ: NVCR ) in light of FDA approval of its lung cancer treatment and the resulting price action. I previously rated NovoCure a buy for the following reasons: Quarterly results exceeded my expectations with higher revenue growth and aggressive cost management Market tailwinds in the speciality oncology space were accelerating Approved treatments in the core business were continuing to succeed DCF generated price target of $22.10 was 46% upside from today's pricing. Since then, Novocure has risen 34% versus the S&P 500 at 1 [Read more]
IMPACT SNAPSHOT
EVENT TIME:
NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS